Gilead Sciences, Inc. vs Marriott International Inc — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Marriott International Inc trades at $349.48 (market cap $90.86B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | MAR | |
|---|---|---|
Market Cap | $164.99B | $90.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $402.54 |
52-Week Low | $110.56 | $259.04 |
Enterprise Value | $188.06B | $108.17B |
Dividend Yield | 2.47% | 0.84% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →